Ductal carcinoma is a prevalent form of breast cancer that originates in the milk ducts, comprising a significant portion of breast cancer diagnoses. Cancer research has delved into understanding its molecular mechanisms, risk factors, and treatment options. Studies highlight the role of genetic mutations, such as BRCA1 and BRCA2, in predisposing individuals to ductal carcinoma. Moreover, advancements in imaging techniques like MRI and molecular profiling have improved early detection and personalized treatment strategies. Targeted therapies, such as HER2 inhibitors and hormone therapies, have shown promising results in managing ductal carcinoma, enhancing survival rates, and reducing recurrence. Ongoing research aims to further elucidate the complexities of this disease, paving the way for more effective interventions and improved outcomes for patients.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China